Novel therapy for COPD
- 1 January 2000
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 9 (1) , 3-23
- https://doi.org/10.1517/13543784.9.1.3
Abstract
The incidence of chronic obstructive pulmonary disease (COPD) is increasing throughout the world. Much less is known about the pathogenesis of COPD than that of asthma and there is little response to current therapy. Most patients with COPD have acquired their lung disease through smoking cigarettes, and the major step in management is to minimise further damage by stopping this habit. A number of therapies are being developed for the treatment of COPD; including new bronchodilators such as tiotropium bromide, agents to block inflammation induced by neutrophils and macrophages, as well as strategies to combat proteases and oxidants. The long-term goal is to provide therapy that retards the accelerated loss of lung function occurring in COPD. Development of novel therapies for COPD requires reliable Phase II decision making before entering large scale Phase III studies. The patient with COPD is often overlooked compared to their asthmatic counterpart, who benefit from an urgent need to identify novel targets and better therapy.Keywords
This publication has 113 references indexed in Scilit:
- EUROSCOP, ISOLDE and the Copenhagen City Lung StudyThorax, 1999
- Infection of Mice with Mycobacterium bovis–Bacillus Calmette-Guérin (BCG) Suppresses Allergen-induced Airway EosinophiliaThe Journal of Experimental Medicine, 1998
- Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patientsThorax, 1997
- Anti-inflammatory Effects of Theophylline: Modulation of Cytokine ProductionAnnals of Allergy, Asthma & Immunology, 1996
- IL-12: a key cytokine in immune regulationImmunology Today, 1996
- Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways diseaseLife Sciences, 1995
- Muscarinic receptor subtypes in airwaysLife Sciences, 1993
- ONO-5046, a novel inhibitor of human neutrophil elastaseBiochemical and Biophysical Research Communications, 1991
- Dose response relation to oral theophylline in severe chronic obstructive airways disease.BMJ, 1988
- A Comparison of the Bronchodilating Effects of a Beta-2 Adrenergic Agent (Albuterol) and an Anticholinergic Agent (Ipratropium Bromide), Given by Aerosol Alone or in SequenceNew England Journal of Medicine, 1986